Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Triple combination of metformin, DPP4 inhibitor and Thiazolidinedione would be a good option
in the treatment of drug-naïve Korean type 2 diabetic patients. Newly developed
thiazolidinedione, Lobeglitazone would be not inferior to Pioglitazone.